<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380289</url>
  </required_header>
  <id_info>
    <org_study_id>OGTT1</org_study_id>
    <nct_id>NCT00380289</nct_id>
  </id_info>
  <brief_title>Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension</brief_title>
  <official_title>Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <brief_summary>
    <textblock>
      Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide&#xD;
      diuretics or beta blockers or combination of the two?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be comparing the two most commonly used drugs to treat hypertension, atenolol and&#xD;
      bendrofluazide, in patients for whom the drugs (and the doses to be used) are licenced.&#xD;
&#xD;
      We propose an initial open label pilot study of 10-12 patients to confirm final doses to be&#xD;
      tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses&#xD;
      selected. The pilot study will also be used to confirm sample size calculations for the main&#xD;
      study.The protocol for the pilot study will be identical to the main study, but there will&#xD;
      not be a placebo phase and the treatment will not be blinded.&#xD;
&#xD;
      The main study will be double-blind, placebo controlled, cross-over study, of approximately&#xD;
      66 patients in which each patient receives in random order, 4 weeks treatment with either&#xD;
      Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg&#xD;
      and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher&#xD;
      dose stated half way through each dosing period. There will be a 1 month placebo wash-out&#xD;
      between each dosing period.&#xD;
&#xD;
      At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation&#xD;
      Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be&#xD;
      drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 0.5, 1&#xD;
      and 2 hours.&#xD;
&#xD;
      Blood pressure will be measured at each study visit using an Omron machine. The patients will&#xD;
      also be given a blood pressure machine to take home and will be asked to measure and record&#xD;
      their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or&#xD;
      over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the&#xD;
      patient will be asked to contact study staff. If the blood pressure remains over 160/110 for&#xD;
      two measurements, then another antihypertensive therapy may be commenced, or the patient&#xD;
      withdrawn from the study. If blood pressure is &lt; 110/70 mmHg with symptoms then a decision&#xD;
      may be made to terminate their participation in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Do patients show a similar change in glucose tolerance after thiazide or beta blocker therapy?</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does the combination of drugs cause a greater reduction in glucose tolerance than expected from the response to each drug taken alone?</measure>
  </secondary_outcome>
  <enrollment>66</enrollment>
  <condition>Essential Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiazide and beta blocker</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteers will be aged 18-75 years.&#xD;
&#xD;
          -  Hypertension- either&#xD;
&#xD;
               -  untreated, BP 140-170/90-110&#xD;
&#xD;
               -  treated for over 1 month with drugs other than beta blockers or diuretic and&#xD;
                  BP&gt;140/85&#xD;
&#xD;
               -  treated for over 1 month with drugs other than beta blockers or diuretic and&#xD;
                  BP&lt;140/85 and patient willing to change medication for eight months.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any patient already taking thiazide diuretics or beta blockers in whom these drugs&#xD;
             cannot be switched to alternative drugs with similar or better blood pressure control.&#xD;
&#xD;
          -  Any patient who is intolerant of these medications will be excluded from the study.&#xD;
&#xD;
          -  Patients with gout, asthma or any other contraindications to the study drugs will be&#xD;
             excluded.&#xD;
&#xD;
          -  Women of child bearing age not using contraception.&#xD;
&#xD;
          -  Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g.&#xD;
             cancer)&#xD;
&#xD;
          -  Volunteers not able to give informed consent&#xD;
&#xD;
          -  Patients with diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor MJ Brown, MA MSC MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addenbrookes Hosptal NHS Trust/ University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Professor MJ Brown, MA MSC MD FRCP</last_name>
    <phone>01223 762577 (UK)</phone>
    <email>mjb14@medschl.cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr A Stears, MBBS BSc MRCP</last_name>
    <phone>01223 586865 (UK)</phone>
    <email>as659@medschl.cam.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrs M Watts</last_name>
      <phone>01223 586865</phone>
      <email>mw363@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dr A Stears, MBBS BSc MRCP</last_name>
      <phone>01223 586878</phone>
      <email>as659@medschl.cam.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 22, 2006</study_first_submitted>
  <study_first_submitted_qc>September 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <last_update_submitted>September 22, 2006</last_update_submitted>
  <last_update_submitted_qc>September 22, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2006</last_update_posted>
  <keyword>Essential hypertension</keyword>
  <keyword>Glucose metabolism</keyword>
  <keyword>Thiazides</keyword>
  <keyword>Beta blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

